Compare W W Grainger Inc (GWW) vs GeneDx Holdings Corp (WGS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
W W Grainger Inc vs GeneDx Holdings Corp — how do they compare? W W Grainger Inc trades at $1,399.29 (market cap $64.75B), while GeneDx Holdings Corp trades at $61.42 (market cap $1.96B). The key difference: W W Grainger Inc is far larger — about 33× GeneDx Holdings Corp's market cap, and W W Grainger Inc pays a 0.68% dividend while GeneDx Holdings Corp pays none. Which is the better fit depends on your goals.
| GWW | WGS | |
|---|---|---|
Market Cap | $64.75B | $1.96B |
Sector | Technology | Technology |
52-Week High | $1.39K | $167.51 |
52-Week Low | $918.18 | $34.51 |
Enterprise Value | $66.84B | $1.96B |
Dividend Yield | 0.68% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GWW trades at $1,391.07, up 1.46% with strong technical momentum and bullish moving averages. The company reported solid Q1 2026 earnings of $11.65 per share, beating estimates, and raised full-year guidance. With revenue growth to $18.4B and net profit margin improving to 9.69%, fundamentals remain robust despite elevated valuation multiples.
Outlook remains positive with analyst consensus price target of $1,260 offering modest upside. Key risks include high P/E ratio of 36.88 and competitive pressures in industrial distribution. The stock presents a quality growth opportunity but requires monitoring of valuation sustainability amid economic uncertainties.
WGS trades at $62.73, up 0.48% on the day, amid a bearish technical signal and negative earnings momentum. The stock faces significant headwinds from a class action lawsuit alleging securities fraud tied to a 49% stock decline, while fundamentals show a net loss of $21.02 million in 2025 and deteriorating profitability into 2026. Analyst consensus remains bullish with a $75.40 price target, but recent news flow is overwhelmingly negative.
The outlook is clouded by legal risks and weak financial performance, though analyst optimism suggests potential recovery if the company can stabilize operations. Key risks include litigation outcomes, execution on profitability, and market sentiment shifts. The stock's trajectory hinges on resolving legal challenges and demonstrating sustainable earnings improvement.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About W W Grainger Inc
Grainger is a leading broad-line distributor of maintenance, repair, and operating (MRO) products. It serves millions of customers worldwide through an integrated network of branches and digital platforms.
Read more on GWW →About GeneDx Holdings Corp
GeneDx is a patient-centered health intelligence company that specializes in transforming healthcare through the application of genomics. It combines advanced technology with one of the world's largest rare disease genomic datasets to provide clinical-grade exome and genome sequencing, enabling precise and rapid diagnosis for patients with complex medical conditions.
Read more on WGS →
